MAYJUNE

MayJune is a clinical-stage biotechnology company focused on the discovery and development of novel precision oncology therapeutics. The company specializes in targeting the DNA damage response (DDR) and the ubiquitin-proteasome system (UPS) to treat genetically defined cancers. Its lead candidate, MJ001, is a potent and selective small molecule inhibitor of Ubiquitin-specific protease 1 (USP1), which is currently in Phase 1 clinical development for patients with advanced solid tumors, including those with BRCA mutations. MayJune aims to address resistance mechanisms in cancer by leveraging synthetic lethality and other innovative biological insights. The company maintains operations in both the United States and China to accelerate its global development strategy.